Connect with us

Hi, what are you looking for?

Economy

Peso may climb vs the dollar on BSP easing, vaccine news

THE PESO may strengthen against the dollar this week after the central bank cut borrowing costs anew and on continued progress in trials for coronavirus disease 2019 (COVID-19) vaccine candidates.

The local unit closed at P48.23 on Friday, rising by 8.5 centavos from its P48.315 finish on Thursday, data from the Bankers Association of the Philippines showed.

Week on week, however, the peso declined by two centavos from its P48.21 finish on Nov. 13.

Rizal Commercial Banking Corp. Chief Economist Michael L. Ricafort said the peso strengthened after the Bangko Sentral ng Pilipinas (BSP) slashed key interest rates to new record lows.

“This will help boost economic recovery prospects in terms of further reducing borrowing costs, spur greater demand for loans that boost investments, jobs, economic opportunities, and more gains in the local financial markets,” Mr. Ricafort said.

The BSP Monetary Board on Thursday unexpectedly slashed benchmark interest rates by another 25 basis points to accelerate economic recovery amid the surge of COVID-19 cases in certain countries.

This brought down the rates on the BSP’s overnight reverse repurchase, lending and deposit facilities to new record lows of 2%, 2.5%, and 1.5%, respectively.

For this week, Mr. Ricafort said the peso may continue rising as the government disburses more funds out of the P165.5 billion programmed under Republic Act 11494 or the Bayanihan to Recover as One Act.

“The peso could be stronger with faster utilization of the Bayanihan II Law funds that could lead to faster economic recovery,” he said in an e-mail.

Meanwhile, a trader said the peso may also strengthen as drug companies advance in their development of COVID-19 vaccines.

Pharmaceutical companies and research centers around the world are working on potential COVID-19 vaccines, with large global trials of several of the candidates involving tens of thousands of participants underway, Reuters reported.

The US Food and Drug Administration’s outside advisers will meet on Dec. 10 to discuss whether to authorize the COVID-19 vaccine developed by Pfizer, Inc. and German partner BioNTech for emergency use, the agency said on Friday.

Meanwhile, AstraZeneca started late-stage trials on Saturday of an experimental long-acting monoclonal antibody combination drug it hopes could be used as a so-called prophylactic to prevent COVID-19 infection in at-risk people for up to 12 months.

The dollar on Friday rose against major currencies such as the euro and yen, with traders consolidating positions amid competing forces that pull the currency in different directions: the surge in virus cases, on the one hand, and positive vaccine news, on the other.

For this week, Mr. Ricafort sees the peso moving from P48.10 to P48.35 versus the dollar, while the trader expects it to range from P48.15 to P48.30. — KKTJ with Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

Latest

Top News

Intensifying focus on worker safety across medical, chemical, automotive, and oil & gas sectors is a major reason for the burgeoning nitrile gloves industry,...

Economy

The government expects to finish 29 flagship infrastructure projects worth P238.48 billion before President Rodrigo R. Duterte’s term ends in 2022. It has added...

Economy

The Philippine central bank raised its balance of payment (BoP) projection for this year on expectations of an improved economic landscape here and overseas....

Economy

The Philippine central bank raised P100 billion from its auction of short-term securities on Friday even as rates rose on hints by the US...

Economy

The country’s outstanding foreign debt fell by 1.5% or $1.4 billion to $97 billion at the end of March from end-December, after the National...

Economy

The Department of Health (DoH) reported 6,833 coronavirus infections on Friday, bringing the total to 1.35 million. The death toll rose by 110 to...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Investing

As a traditionally rigid insurance industry becomes bogged down by antiquated processes and operations, a handful of industry leaders are seeking to shake things...

Economy

US President Joseph R. Biden, Jr., will rely on ally countries to supply the bulk of the metals needed to build electric vehicles and focus on...

Economy

THE Securities and Exchange Commission (SEC) has warned the public from investing or to stop any investment in a group named Maxxprofit Computer Trading...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.



Your information is secure and your privacy is protected. By opting in you agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!